SCHEDULE: RA Capital Reports Dilution in Cidara Therapeutics Stake

RA Capital Management and its affiliates reported a dilution of their beneficial ownership in Cidara Therapeutics, Inc. to 10.7% due to new share issuances by the company.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") filed Amendment No. 4 to their Schedule 13D.
• The amendment reports a dilution of the Reporting Persons' beneficial ownership in Cidara Therapeutics, Inc. common stock, which was not a result of any acquisition or disposition of securities by the Reporting Persons.
• The Reporting Persons collectively beneficially own 3,372,923 shares of common stock, representing 10.7% of the class.
• This percentage is based on 31,439,371 shares of common stock outstanding as of November 3, 2025.
• RA Capital Healthcare Fund, L.P. directly holds 3,365,523 shares of common stock, Series A preferred stock convertible for up to 6,296,920 shares, and pre-funded warrants exercisable for up to 1,286,786 shares.
• These convertible securities contain "Beneficial Ownership Blockers" which preclude conversion or exercise if it would result in ownership exceeding 9.99% of the common stock outstanding, and the Fund is currently prohibited from converting/exercising due to these blockers.
• An option to purchase 7,400 shares of common stock, part of a larger 22,200 share option, is scheduled to vest on January 3, 2026, with an exercise price of $26.62 per share.

Sentiment

Score: 4

Explanation: The filing reports a dilution of a significant investor's stake, which is generally a neutral to slightly negative event for the investor if not accompanied by a value-accretive event for the company. The company's implied issuance of shares could be positive if for a strategic purpose, but the filing itself doesn't provide that context. The 'Beneficial Ownership Blockers' also limit the investor's flexibility.

Negatives

• The Reporting Persons' beneficial ownership percentage in Cidara Therapeutics, Inc. has been diluted to 10.7%.
• Beneficial Ownership Blockers prevent the conversion of preferred stock and exercise of pre-funded warrants, limiting the Reporting Persons' ability to increase their stake beyond 9.99% through these instruments.

Risks

• The existence of "Beneficial Ownership Blockers" limits the ability of RA Capital Healthcare Fund, L.P. to convert its Preferred Stock or exercise its Pre-Funded Warrants if doing so would result in ownership exceeding 9.99% of the common stock outstanding.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Cidara Therapeutics, Inc. It primarily details the current beneficial ownership status of the Reporting Persons.

Industry Context

This filing indicates a change in a significant institutional investor's stake in a biotechnology company. Dilution often occurs in the capital-intensive biotech industry through secondary offerings or other equity financing rounds to fund research and development or operations.

Comparison to Industry Standards

• The 9.99% beneficial ownership blocker is a common provision in convertible securities to prevent triggering certain regulatory thresholds or change-of-control provisions, which is standard practice in investment agreements.
• Institutional investors like RA Capital Management frequently take significant stakes in biotechnology companies, often providing capital and strategic guidance.

Stakeholder Impact

• Shareholders: Existing shareholders (including RA Capital) experience dilution of their percentage ownership due to the issuance of new shares by the company.
• RA Capital Management: Their percentage ownership has decreased, and their ability to increase their stake via conversion of existing preferred stock and warrants is capped by beneficial ownership blockers.

Next Steps

• Vesting of additional stock options for 7,400 shares on January 3, 2026.
• Future vesting of the remaining 2/3rds of the 22,200 total stock options in equal monthly installments over a two-year period.

Key Dates

Recommendation

The filing primarily details a change in beneficial ownership due to dilution, not a direct transaction by the reporting persons. While dilution can be a concern, the filing does not provide sufficient information about the underlying reason for the company's share issuance (e.g., a strategic acquisition, clinical trial funding, or general operations) to warrant a strong buy or sell recommendation. The continued significant stake by RA Capital, despite dilution, suggests ongoing interest. Investors should await further company disclosures regarding the purpose and terms of the dilutive event.

Keywords

Cidara Therapeutics, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Common Stock, Dilution, Preferred Stock, Pre-Funded Warrants, SEC Filing, Investment Management, Biotechnology